Background: Overall treatment time is an important factor in the outcome of cervix cancer treatment. However, in daily clinical practice, unplanned treatment interruptions are inevitable for many reasons. We performed a prospective study to assess the overall treatment time for patients treated in our department and identify the causes of treatment prolongation. Material and methods: Between first January and 30 April 2016, a group of patients with locally advanced cervix cancer was interviewed at the end of treatment. Data was collected using a questionnaire containing important study parameters. Results: 100 patients were interviewed. The mean age of women was 55,08 ± 12,43 years. Seventy-five patients (75%) were illiterate. Ninety-six patients (96%) has low socio-economic level. Ninety patients (90%) has squamous cell carcinoma. The stage IIIB represented the majority of cases (90%). All patients were treated with concurrent chemoradiation except one patient. Pelvic radiation at the dose of 46 Gy was performed for all patients. The median time to complete pelvis RT was 37 days (34-42 days). Only seventy-seven patients (77%) were treated by BT. A median time of the first brachytherapy insertion was 13,50 days (0-20 days). The median of OTT was 71 days (64-78 days). This prolongation was mainly due to the delay of the first brachytherapy insertion. In the univariate and multivariate analysis, 2 factors were associated with longer overall treatment time: age (p=0,006) and stage (p=0,001). Conclusion: In our country, cervical cancer outcomes are still poor. To improve the prognosis, overall treatment time should be given in timely manner (8weeks).
INTRODUCTION
One of the main principles of radiotherapy (RT) is to deliver the total fractionated dose without interruptions and without a prolongation of the overall treatment time (OTT). However, in daily clinical practice, unplanned treatment interruptions are inevitable for many reasons (1) . This fact has been studied for a number of tumor sites (2, 3) and has included both unplanned and planned interruptions. Several retrospective single-institution studies have demonstrated that the duration of radiotherapy can negatively affect cervical cancer outcomes. Prolongation of the radiation course in these studies was associated with a decrease of 0.5% to 1.2% in pelvic control and cause-specific survival per additional day of treatment (4, 5) . The adverse effects of prolonged radiation have been demonstrated in head and neck cancers as well (5, 6) . A possible physiologic mechanism for these adverse outcomes is accelerated tumor cell repopulation during RT when there is a lag period after initiation of radiation (7) . We performed a prospective study to assess the OTT in a cohort of 100 patients treated in our department for locally advanced cervix cancer and identify the causes of OTT prolongation To improve therapeutic management.
METHODS

Patients
This retrospective study was conducted during the period from the first January to 30 April 2016 at the National Institute of Oncology in Rabat. During that time, 100 patients with locally advanced cervix cancer were interviewed at the end of treatment after obtaining oral consent from each patient (all the patients were informed of the necessity to continue their treatment).
Data collection
Structured face to face questionnaire was conducted by previously trained resident interviewers. The supplemented information has been filled from patient medical records. Data was collected using a questionnaire containing important study parameters which derived from existing literature of the impact of OTT in the therapeutic care. The record collection includes social and demographic data: age at presentation (years), occupation (no occupation, housewife, retired, full time or part time employed), patient educational level (illiterate, primary, secondary or higher education), marital status (single, married, widowed or divorced), number of dependent children, personal residence, residence during the treatment (personal address, hospital, hostel), transport ( walking, personal transport, public transport), duration of transport ( 5min, 5-20 min, 20-40 min, 40-60 min, ≥ 60 min). Data included also : previous medical history, date of diagnosis, classification of disease (TNM classification), histologic type, number of cycle of chemotherapy, drugs used, follow-up during chemotherapy, external beam RT doses, fractionated dose, time of both treatment start and end to evaluate OTT, causes of OTT prolongation (machine breakdowns and servicing, public holidays, treatment toxicities, appointment delay of brachytherapy or RT).
Treatment modalities
The treatment adopted in our department is concurrent chemoradiotherapy with weekly chemotherapy. Radiation therapy: a total dose of 66 to 70 Grays (Gy) was delivered to all patients, using either a combination of external beam radiation therapy (EBRT) and brachytherapy (BT). EBRT was used alone when BT was not feasible. High-dose-rate (HDR) brachytherapy was performed. Four fractions of 7 Gy were prescribed when HDR-BT was performed. The technical limitation was the absence of interstitial catheters in our department, enabling us to perform BT when an involvement of the lower vagina with a thickness of more than 5 mm was reported and also in the cases where the uterus was involved, because of the difficulty to ensure a full coverage of the tumor without interstitial catheters. When parametrial involvement was documented, an additional dose of 10 Gy in five fractions was delivered. Also, an additional dose of 10 to 20 Gy was systematically delivered to any proven positive lymph nodes. Otherwise, positive lymph nodes were included in the target volume of the second phase of the EBRT treatment.
As to concomitant chemotherapy, Cisplatin is the most commonly used drug and was delivered weekly throughout the course of RT at a dose of 40 mg/m2 (maximum dose of 70 mg weekly) as long as the treatment was well tolerated. OTT was calculated from the first day of EBRT to the last day of BT or EBRT, whichever was last to complete. Fifty-six days (8 weeks) was used as a limit, as it was the recommended time to complete RT in Gynecology Oncologic Group (GOG) and National Comprehensive Cancer Network (NCCN).
Statistical analysis
Statistical analysis of the data was carried out by the SPSS 20.0. Qualitative variables were presented as number and percentages. Quantitative variables were presented as a mean ± standard deviation for variables with normal distribution, and as median and interquartile range (IQR) for variables with skewed distributions. A multivariate logistic regression was used to determine factors associated with prolongation of OTT. We chose a value of p less than or equal to 0.2 for inclusion in the multivariate analysis. In all tests, the values p < 0.05 were regarded statistically significant.
RESULTS
Study population
In all, 100 patients were interviewed. The mean age of women was 55,08 ± 12,43 years. Seventy-five patients (75%) were illiterate. Ninety-six patients (96%) has a low socio-economic level. 54% of cases were resident in the hostel. previous medical history of hypertension, and five patients (5%) had diabetes (table 1) . Ninety patients (90%) has squamous cell carcinoma. The stage IIIB represented the majority of cases (90%). 
Treatment results
All patients were treated with concurrent chemoradiation except one patient. She was treated by EBRT only because of poor tolerance to chemotherapy. Pelvic radiation at the dose of 46 Gy was performed for all patients. The median time to complete pelvis RT was 37 days (34-42 days).
Seventy-seven patients (77%) were treated by BT. A median time to the first BT insertion was 13,50 days (0-20 days). The median of OTT was 71 days (64-78 days) ( 
DISCUSSION
Contemporary treatment for locally advanced cervical cancer, commonly defined as stage IB2 to IVA disease, consists of radiotherapy and chemotherapy (chemoradiation). Radiotherapy includes EBRT to the whole pelvis, along with BT delivered locally to the cervix. Concurrent chemoradiation became the standard of care in 1999 with the publication of 5 clinical trials demonstrating that the addition of chemotherapy to the radiation regimen confers a substantial survival benefit (8) . The patterns of failure after RT are predominantly locoregional, and the cervix is one of the treatment sites for which the effect of OTT has also been studied (4, 9) . However, the combination of EBRT with BT makes the treatment schedule more complicated with many different OTTs. Several retrospective studies have demonstrated a negative impact of treatment breaks and prolonged OTT on the outcome (4, 9) . Fyles showed a loss of local control approximated 1% per day for treatment prolongation 30 days, especially in locally advanced stages (III-IV) (4) . In an analysis of 837 patients from the Patterns of Care Study treated with doses of 65.99 Gy or greater for squamous cell carcinoma of the uterine cervix, Lanciano et al. reported a highly significant decrease in pelvic tumor control and survival with prolongation of treatment times. They described a 4-year actuarial infield recurrence rise from 6 to 20% when total treatment time increased from 6 weeks or less to 10 weeks (p = 0.0001). This translated into significantly decreased survival. The clinical stage of the tumor and overall treatment time were significant prognostic factors for infield recurrence (10) . Prolongation of treatment time in patients with Stage IB, IIA, IIB, and III carcinoma of the uterine cervix has a significant impact on pelvic tumor control and Cause-Specific Survival. The effect of OTT was present regardless of tumor size except in Stage IB tumors ≤3 cm. Regression analysis of results confirmed that OTT prolongation resulted in a decreased local control rate by 0.85% per day for all patients, with a major decrease in Stage IIB and Stage III patients. Perez et al. concluded that the irradiation for patients with invasive carcinoma of the cervix should be delivered in the shortest possible overall time (11) . In Chen's study, patients with Stage IB-IVA patients who were treated with EBRT and high HDR BT have pelvic failure rate increased if BT was delayed 4.5 weeks (9) . After completion of wholepelvis RT, three to four HDR BT applications were performed at 1-week intervals. The median OTT, calculated from the first day of EBRT to the last day of BT insertions, was 63 days. When all disease stages were pooled together, the 5-year pelvic control rate and cause-specific survival were greater for the patients who completed treatment in 63 days. The OTT was an independent prognostic factor for pelvic control and cause specific survival (9) . Song et al. performed a single-institution retrospective study on 113 women who were treated with chemoradiation from 1997 to 2009. They found that OTT of greater than 8 weeks was associated with increased pelvic tumor recurrence, but not distant site recurrence or cause-specific survival (12) . Tumor cells rapid repopulation during radiation treatment and/ or accelerated repopulation were the most likely mechanism explaining the relationship between OTT prolongation and poor outcomes (13) . The onset of accelerated repopulation occurs after 19 days of treatment start. Consequently, the typically prescribed radiotherapy dosages fall short of eradicating rapidly expanding tumor cells when treatment is protracted (14, 15) . Moreover, several studies questioned the importance of reducing OTT in the presence of chemotherapy that may hinder tumor cell repopulation (12, 13, 14, 15, 16) . Nevertheless, Jhawar et al. suggest that prolongation of OTT beyond 7 weeks increases mortality hazard ratio by 21% (p=0.002) (13) , highlighting that tumor cells repopulation is potentially not restricted to the definitive setting and cannot be overcome by chemotherapy (17) . In contrast, The RTOG's trial compared a split-course versus conventionally fractionated pelvic RT regimen for Stage IIB-IVA cervical carcinoma. They concluded that 2-week gap did not cause any difference in local control (18) . Other retrospective study evaluating the effect of OTT on survival and toxicity of radical RT for cervical cancer showed that 66% had at least one gap treatment. The authors didn't find an effect of treatment gap (p=0,43) or an increased OTT (p=0,79) on the cause-specific survival of patients. There was significantly more grade 4 morbidity in those patients treated over a short period (29-32 days) compared to the rest. Possibly related to the loss of RT free days to weekend intracavity insertions (19) . A single-institution retrospective study on 166 women treated with chemoradiation from 1989 to 2009 found that radiation duration of greater than 60 days was not associated with increased pelvic tumor recurrence or cause-specific survival (16) . Several factors were found to be associated with prolonged radiation duration for cervical cancer. The Later stage at diagnosis increased the odds of receiving prolonged care. Perhaps this could be explained by a higher risk of complications for those with more advanced stages (8) . In our study, age (p=0,006) and stage (p=0,001) were the factors associated with longer OTT. High-dose-rate BT is gaining wider acceptance worldwide. Multiple insertions are required. If HDR BT starts only after completion of EBRT, the OTT would be unduly prolonged. The recommendation is to start HDR BT during EBRT. Although it should be mandatory not to give EBRT on the day of HDR-BT [1] . Also, it was reported that patients treated using a twice-weekly HDR BT schedule had better local recurrence-free survival than did patients treated using once-weekly BT when the implants were inserted after EBRT completion (20) . The recommended duration from the American Brachytherapy Society is to keep the total treatment duration to 8 weeks (21) . The gaps can occur between EBRT and BT or between the fractionated BT sessions. In our study, there was a gap between EBRT and BT. It was on average 12,85 days. This fact was mainly due to the additional workload of patients initially treated in other oncology centers and who were referred to us for BT. Our BT department is a national reference center. It includes experienced medical experts. During our study, four insertions per day were required. But it was not sufficient to treat all patients within 56 days. The BT can be started earlier than planned in the case of an inevitable gap during EBRT (1) . In the case of low dose rate brachytherapy, a higher total dose can be given by the use of a lower prescription dose rate. Where low dose rate treatment is interrupted for patient-related reasons, the remainder of the treatment can be given by high dose rate techniques, providing a method of dose recalculation is used. For patients treated with HDR-BT, the remaining fractions and interfraction intervals in the remaining treatment period should be adjusted properly using the same principles described for EBRT (22) . Each of the methods has limitations, but the methods should be considered if interruption and prolongation of the OTT are inevitable. Different compensation methods have been modeled and compared (22, 23, 24) , but no clinical data are available to substantiate the strategy choice. The best approach is to spend much effort to retain the planned fractionation schedule and the quality of the RT treatment (1) . The NCCN Cervical Cancer Guidelines recommend that chemoradiation is completed within 8 weeks (25) , and this is being proposed as a quality measure for cervical cancer treatment. Current RTOG protocol (RTOG1174) recognizes the treatment duration extension beyond 67 days as an unacceptable deviation (13) . Although it is difficult to define an optimal OTT for radical RT for cervical carcinomas, the entire RT course should be completed in a timely fashion, and delays and split treatments should be avoided whenever possible.
CONCLUSION
In Morocco, cervical cancer is still diagnosed at an advanced stage. The outcomes are still poor. To improve the prognosis, OTT should be given in a timely manner (8 weeks) . Prospective observational studies to evaluate the association of radiation duration on recurrence in the era of chemoradiation and reasons for prolonged radiation are warranted.
CONSENT SECTION Written informed consent was obtained from all patients for publication of this study and any accompanying images.
